Ex­clu­sive: Ae­glea re­brands to Spyre, names new CEO in IBD race against TL1A drugs at Mer­ck, Roche and Sanofi

Ae­glea Bio­Ther­a­peu­tics will as­sume the name of the drug de­vel­op­er it re­verse merged with ear­li­er this year, Spyre Ther­a­peu­tics, as the biotech fo­cus­es on its race against TL1A an­ti­bod­ies at Mer­ck, Roche and Sanofi.

In con­junc­tion with the name change, it al­so el­e­vat­ed Spyre op­er­at­ing chief Cameron Tur­tle to the post of CEO, poached a trio of lead­ers from com­peti­tor Prometheus Bio­sciences and added two new board mem­bers: for­mer Blue­print Med­i­cines CEO Jeff Al­bers and Re­NA­gade Ther­a­peu­tics CFO Lau­rie Stelz­er. Spyre will trade as $SYRE start­ing Tues­day morn­ing, re­plac­ing $AGLE, which had fal­tered in the clin­ic with a rare dis­ease treat­ment can­di­date ear­li­er this year that led it to seek al­ter­na­tive paths.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER